FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

ME Erwin

Research Profile

Procedures

Microbial Sensitivity Tests

Chemicals & Drugs

Physiology

Microbial Drug Resistance

Activities & Behaviors

Quality Control

Living Beings

Co-author Network

Publications

TOP 3
ME Erwin; A M Fix; Ronald Jones
Three independent yearly analyses of the spectrum and potency of metronidazole: a multicenter study of 1,108 contemporary anaerobic clinical isolates.
Ronald Jones; ME Erwin
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.
SA Marshall; ME Erwin; Ronald Jones
Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of ME Erwin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2001: ME Erwin; A M Fix; Ronald Jones
Three independent yearly analyses of the spectrum and potency of metronidazole: a multicenter study of 1,108 contemporary anaerobic clinical isolates.
Diagnostic microbiology and infectious disease 2001;39(2):129-32.
2000: Ronald Jones; ME Erwin
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 2000;37(3):195-201.
2000: SA Marshall; ME Erwin; Ronald Jones
Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group.
Journal of clinical microbiology 2000;38(6):2462-3.
2000: Ronald Jones; Lalitagauri M Deshpande; ME Erwin; MS Barrett; Mondell L Beach
Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
The Journal of antimicrobial chemotherapy 2000;45 Suppl 1():67-70.
2000: B A Odland; ME Erwin; Ronald Jones
Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications.
Journal of clinical microbiology 2000;38(1):453-5.
1999: Ronald Jones; ME Erwin; Douglas J Biedenbach; DM Johnson; Michael A Pfaller
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
Diagnostic microbiology and infectious disease 1999;35(3):227-34.
1999: Ronald Jones; SA Marshall; ME Erwin
Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):103-10.
1999: C L Hayward; ME Erwin; MS Barrett; Ronald Jones
Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates.
Diagnostic microbiology and infectious disease 1999;34(2):99-102.
1999: Ronald Jones; DM Johnson; ME Erwin; Mondell L Beach; Douglas J Biedenbach; Michael A Pfaller
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):91-8.
1999: Ronald Jones; Douglas J Biedenbach; ME Erwin; Mondell L Beach; Michael A Pfaller
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Journal of clinical microbiology 1999;37(6):1999-2002.
1999: Ronald Jones; KC Kugler; ME Erwin; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;33(4):247-53.
1999: DM Johnson; Ronald Jones; ME Erwin
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
Diagnostic microbiology and infectious disease 1999;33(2):87-91.
1999: SA Marshall; Ronald Jones; ME Erwin
Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;33(1):19-25.
1998: G V Doern; Michael A Pfaller; ME Erwin; Angela B Brueggemann; Ronald Jones
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 1998;32(4):313-6.
1998: Ronald Jones; ME Erwin
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1998;32(1):55-64.
1998: Ronald Jones; Michael A Pfaller; G V Doern; ME Erwin; Richard J Hollis
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Diagnostic microbiology and infectious disease 1998;30(3):215-28.
1998: G V Doern; Ronald Jones; Michael A Pfaller; ME Erwin; C Ramirez-Rhonda
Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1998;30(2):113-9.
1997: Ronald Jones; SA Marshall; Michael A Pfaller; Werner W Wilke; Richard J Hollis; ME Erwin; Michael B Edmond; Richard P Wenzel
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.
Diagnostic microbiology and infectious disease 1997;29(2):95-102.
1997: ME Erwin; D Varnam; Ronald Jones
In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.
Diagnostic microbiology and infectious disease 1997;28(2):93-100.
1997: Ronald Jones; MS Barrett; ME Erwin
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Antimicrobial agents and chemotherapy 1997;41(2):488-93.
1996: Ronald Jones; ME Erwin; J L Croco
Critical appraisal of E test for the detection of fluoroquinolone resistance.
The Journal of antimicrobial chemotherapy 1996;38(1):21-5.
1996: Ronald Jones; DM Johnson; ME Erwin
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrobial agents and chemotherapy 1996;40(3):720-6.
1996: M G Cormican; ME Erwin; SA Marshall; Ronald Jones
Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.
Diagnostic microbiology and infectious disease 1996;24(3):155-60.
1996: S Worth; ME Erwin; Ronald Jones
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials.
Diagnostic microbiology and infectious disease 1996;24(2):87-91.
1995: G V Doern; Ronald Jones; E H Gerlach; J A Washington; D J Biedenbach; A Brueggemann; ME Erwin; C Knapp; J Raymond
Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1.
Journal of clinical microbiology 1995;33(6):1665-7.
1995: J L Croco; ME Erwin; J M Jennings; L R Putnam; Ronald Jones
Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20 Suppl 2():S339-41.
1995: M G Cormican; ME Erwin; Ronald Jones
Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1995;22(1-2):119-23.
1995: Ronald Jones; ME Erwin; S C Anderson
Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.
Diagnostic microbiology and infectious disease 1995;21(2):95-100.
1995: Ronald Jones; Helio S Sader; ME Erwin; S C Anderson
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
Diagnostic microbiology and infectious disease 1995;21(2):85-93.
1995: Helio S Sader; Bruce A Runyon; ME Erwin; Ronald Jones
Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis.
Diagnostic microbiology and infectious disease 1995;21(2):105-10.
1995: Ronald Jones; E N Kehrberg; ME Erwin
Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.
Drugs 1995;49 Suppl 2():179-81.
1994: J L Croco; ME Erwin; J M Jennings; L R Putnam; Ronald Jones
Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis.
Diagnostic microbiology and infectious disease 1994;20(4):213-9.
1994: Ronald Jones; Helio S Sader; ME Erwin
Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.
Diagnostic microbiology and infectious disease 1994;20(2):93-8.
1994: S P Murphy; ME Erwin; Ronald Jones
Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.
Diagnostic microbiology and infectious disease 1994;20(1):49-55.
1994: Ronald Jones; E N Kehrberg; ME Erwin; S C Anderson
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.
Diagnostic microbiology and infectious disease 1994;19(4):203-15.
1994: FP Koontz; ME Erwin; MS Barrett; Ronald Jones
Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
Diagnostic microbiology and infectious disease 1994;19(3):183-6.
1994: M J Bale; Ronald Jones; ME Erwin
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1994;19(1):65-8.
1994: Ronald Jones; G V Doern; E H Gerlach; J Hindler; ME Erwin
Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.
Diagnostic microbiology and infectious disease 1994;18(4):243-9.
1994: Ronald Jones; DM Johnson; ME Erwin
Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
Diagnostic microbiology and infectious disease 1994;18(2):125-7.
1994: Ronald Jones; MS Barrett; ME Erwin
In-vitro activity of FK-037, a new parenteral cephalosporin.
The Journal of antimicrobial chemotherapy 1994;33(1):137-44.
1993: J H Hughes; Douglas J Biedenbach; ME Erwin; Ronald Jones
E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.
Journal of clinical microbiology 1993;31(12):3255-9.
1993: SA Marshall; Ronald Jones; P R Murray; JA Washington; S D Allen; E H Gerlach; ME Erwin
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
The Journal of antimicrobial chemotherapy 1993;32(6):877-84.
1993: Douglas J Biedenbach; Ronald Jones; ME Erwin
Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.
Journal of clinical microbiology 1993;31(10):2828-30.
1993: MS Barrett; Ronald Jones; ME Erwin
Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae.
Diagnostic microbiology and infectious disease 1993;17(3):243-5.
1993: Ronald Jones; ME Erwin; H L Hager; P E Hohl
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.
Diagnostic microbiology and infectious disease 1993;17(3):225-32.
1993: MS Barrett; Ronald Jones; ME Erwin
Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeae.
Journal of clinical microbiology 1993;31(9):2531-2.
1993: Helio S Sader; Ronald Jones; JA Washington; P R Murray; E H Gerlach; S D Allen; ME Erwin
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
Diagnostic microbiology and infectious disease 1993;17(2):143-50.
1993: DM Johnson; Ronald Jones; ME Erwin
In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones.
Diagnostic microbiology and infectious disease 1993;17(1):79-83.
1993: Ronald Jones; M J Bale; D Hoban; ME Erwin
In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application.
Diagnostic microbiology and infectious disease 1993;17(1):45-51.
1993: MS Barrett; Ronald Jones; ME Erwin
In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(2):134-41.
1992: Ronald Jones; ME Erwin
Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin.
Diagnostic microbiology and infectious disease 1992;15(8):693-701.
1992: Ronald Jones; ME Erwin; JA Washington; FP Koontz; P R Murray; E H Gerlach
Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.
Diagnostic microbiology and infectious disease 1992;15(7):627-32.
1992: B B Gooding; ME Erwin; MS Barrett; DM Johnson; Ronald Jones
Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.
Antimicrobial agents and chemotherapy 1992;36(9):2049-50.
1992: DM Johnson; ME Erwin; MS Barrett; B B Gooding; Ronald Jones
Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(8):751-5.
1992: Ronald Jones; ME Erwin
In vitro activity of CP-74667 compared with four other fluoroquinolones.
Diagnostic microbiology and infectious disease 1992;15(6):531-6.
1992: Ronald Jones; L B Reller; L A Rosati; ME Erwin; M L Sanchez
Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
Diagnostic microbiology and infectious disease 1992;15(5):425-34.
1992: Ronald Jones; ME Erwin
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.
Journal of clinical microbiology 1992;30(5):1297-300.
1992: Ronald Jones; ME Erwin; MS Barrett
Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
Diagnostic microbiology and infectious disease 1992;15(4):379-81.
1992: ME Erwin; Ronald Jones; FP Koontz; E H Gerlach; P R Murray; JA Washington
MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin.
Journal of clinical microbiology 1992;30(5):1317-9.
1992: ME Erwin; Ronald Jones
Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
Journal of clinical microbiology 1992;30(5):1170-3.
1992: Ronald Jones; ME Erwin; B B Gooding
Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.
Journal of clinical microbiology 1992;30(4):1022-3.
1992: Helio S Sader; ME Erwin; Ronald Jones
In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(4):372-81.
1992: M J Bale; Ronald Jones; ME Erwin; FP Koontz; E H Gerlach; P R Murray; JA Washington
Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.
Journal of clinical microbiology 1992;30(3):744-5.
1992: MS Barrett; Ronald Jones; ME Erwin; FP Koontz
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Diagnostic microbiology and infectious disease 1992;15(2):169-71.
1992: Michael A Pfaller; Ronald Jones; JA Washington; FP Koontz; E H Gerlach; ME Erwin
Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
Diagnostic microbiology and infectious disease 1992;15(2):145-50.
1992: Ronald Jones; ME Erwin
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
Antimicrobial agents and chemotherapy 1992;36(1):233-8.
1992: M J Bale; Ronald Jones; ME Erwin; FP Koontz; E H Gerlach; P R Murray; JA Washington
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.
Journal of clinical microbiology 1992;30(1):225-6.
1991: Ronald Jones; ME Erwin
Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin.
Journal of clinical microbiology 1991;29(12):2890-2.
1991: Ronald Jones; ME Erwin; MS Barrett
Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella.
Diagnostic microbiology and infectious disease 1991;14(6):519-21.
1991: Ronald Jones; ME Erwin; MS Barrett; B M Briggs; DM Johnson
In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester.
Diagnostic microbiology and infectious disease 1991;14(6):473-83.
1991: Ronald Jones; DM Johnson; MS Barrett; ME Erwin
Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.
Journal of chemotherapy (Florence, Italy) 1991;3(5):289-94.
1991: B M Briggs; Ronald Jones; ME Erwin; MS Barrett; DM Johnson
In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
Diagnostic microbiology and infectious disease 1991;14(5):425-34.
1991: Ronald Jones; E H Gerlach; FP Koontz; P R Murray; Michael A Pfaller; JA Washington; ME Erwin; C C Knapp
Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.
Diagnostic microbiology and infectious disease 1991;14(5):383-8.
1991: MS Barrett; Ronald Jones; ME Erwin; DM Johnson; B M Briggs
Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
Diagnostic microbiology and infectious disease 1991;14(5):389-401.
1991: JA Washington; Ronald Jones; S D Allen; E H Gerlach; F P Koontz; P R Murray; Michael A Pfaller; ME Erwin
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.
Antimicrobial agents and chemotherapy 1991;35(7):1508-11.
1991: Ronald Jones; MS Barrett; ME Erwin; B M Briggs; DM Johnson
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Diagnostic microbiology and infectious disease 1991;14(4):319-30.
1991: Ronald Jones; ME Erwin; MS Barrett; DM Johnson; B M Briggs
Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
Diagnostic microbiology and infectious disease 1991;14(4):301-9.
1991: ME Erwin; Ronald Jones; MS Barrett; B M Briggs; DM Johnson
In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.
Antimicrobial agents and chemotherapy 1991;35(5):929-37.
1991: Ronald Jones; E H Gerlach; FP Koontz; P R Murray; Michael A Pfaller; JA Washington; ME Erwin; C C Knapp
Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan.
Journal of clinical microbiology 1991;29(2):363-6.
1990: Ronald Jones; ME Erwin; MS Barrett
In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(11):846-8.
1990: Ronald Jones; J L Croco; MS Barrett; W J Novick; ME Erwin
Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.
Diagnostic microbiology and infectious disease 1990;13(5):371-3.